66698-28-0

Usage

Uses

Used in Pharmaceutical Synthesis:
1-(4-Bromophenyl)piperazine is used as a precursor or intermediate in the synthesis of various pharmaceuticals for its ability to be chemically modified to create new drug candidates.
Used in Organic Chemistry:
In the field of organic chemistry, 1-(4-Bromophenyl)piperazine is utilized as a building block for the creation of complex organic molecules, leveraging its unique structure and reactivity.
Used in Neuropharmacological Research:
1-(4-Bromophenyl)piperazine is used as a research compound in neuropharmacology for its activity as a serotonin receptor agonist, which is crucial for studying the mechanisms of action of drugs targeting the serotonin system.
Used in Treatment of Neurological and Psychological Disorders:
Although still under investigation, 1-(4-Bromophenyl)piperazine is considered for potential use in the treatment of various neurological and psychological disorders due to its interaction with serotonin receptors, which play a significant role in mood regulation and cognitive function.

InChI:InChI=1/C10H13BrN2/c11-9-1-3-10(4-2-9)13-7-5-12-6-8-13/h1-4,12H,5-8H2

Upstream product

• 43204-63-3 bis(2-bromoethyl)amine hydrobromide 
• 106-40-1 4-bromo-aniline 
• 92-54-6 4-phenyl-1-piperazine 
• 334-22-5 N,N-bis(chloro-2-ethyl)amine 
• 589-87-7 1,4-bromoiodobenzene 
• 352437-09-3 tert-butyl 4-(4-bromophenyl)piperazine-1-carboxylate 
• 110-85-0 piperazine 
• 106-37-6 1.4-dibromobenzene 
• 821-48-7 bis-(2-chloroethyl)amine hydrochloride 

Downstream Products

• 678996-43-5 1-acetyl-4-(4-bromo-phenyl)-piperazine 
• 130307-08-3 1-bromo-4-(4-methyl-1-piperazinyl)benzene 
• 401566-20-9 C₂₃H₃₃N₄O₃SBr 
• 357647-98-4 1-(4-bromophenyl)-4-(methylsulfonyl)piperazine 
• 480993-49-5 C₂₆H₂₆BrN₅O₄ 
• 1029401-87-3 C₂₇H₂₈BrN₅O₄ 
• 352437-09-3 tert-butyl 4-(4-bromophenyl)piperazine-1-carboxylate 
• 1394867-75-4 2-{4-[(4-(4-bromophenyl)piperazin-1-yl)methyl]-3-(4-chlorobenzoyl)-5-methylthiophen-2-yl}isoindoline-1,3-dione 
• 1422513-03-8 3-(4-(4-(4-bromophenyl)piperazin-1-yl)butyl)indolin-2-one 
• 1422513-04-9 3-(4-(4-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)piperazin-1-yl)butyl)indolin-2-one 

Relevant academic research and scientific papers

MONOACYLGLYCEROL LIPASE INHIBITORS

Provided are compounds of formula (I), or a pharmaceutically acceptable salt or solvate thereof: Also provided are compositions comprising compounds of formula (I). The compounds and compositions are also provided for use as medicaments, for example as medicaments useful in the treatment of a condition modulated by monoacylglycerol lipase (MAGL). Also provided are the use of compounds and compositions for the inhibition of monoacylglycerol lipase (MAGL).

Novel piperazine based compounds as potential inhibitors for SARS-CoV-2 Protease Enzyme: Synthesis and molecular docking study

Structurally diverse piperazine-based compounds hybrid with thiadiazole, isatin or with sulfur/nitrogen, functionalities were synthesized. The structures of the new compounds were established based on their spectral data and elemental analysis. The physicochemical, bioactivity scores and pharmacokinetic behavior of all the prepared ligands were evaluated using in silico computational tools. The new piperazine ligands have been screened for their inhibition activity against SARS-CoV-2 protease enzyme using molecular docking analysis. The docking studies showed that all the ligands have been docked with negative dock energy onto the target protease protein. Moreover, Molecular interaction studies revealed that SARS-CoV-2 protease enzyme had strong hydrogen bonding interactions with piperazine ligands. The present in silico study thus, provided some guidance to facilitate drug design targeting the SARS-CoV-2 main protease.

COMPOUND SIMULTANEOUSLY INHIBITING LSD1 AND HDAC TARGETS AND APPLICATION THEREOF

A compound having a general structural formula as shown in Formula I: X-AB-Y (Formula I); in the above Formula I, X is selected from any one of -CO2H, -CONHZ, -CH=CH-CO2H, -CH=CH-CONHZ, wherein Z is selected from any one of substituted or unsubstituted C1-C12 alkyl, substituted or unsubstituted aryl, and hydroxyl; Y = -NR1R2, wherein NR1R2 is a substituted or unsubstituted 3- to 9-membered nitrogen-containing heterocycloalkyl; A and B are each independently selected from substituted or unsubstituted phenylene, substituted or unsubstituted azaphenylene. The compound or corresponding pharmaceutical salt thereof can inhibit LSD1 and HDAC target proteins at the same time, thus inhibit the proliferation of many kinds of tumor cells and have good antitumor effect.

ANTI-PAIN COMPOUND AND PREPARATION METHOD THEREFOR

Disclosed are a compound represented by the general Formula (I), or a stereisomer, tautomer, derivative, prodrug or pharmaceutically acceptable salt thereof, and a method for preparing the compound and use of the compound in manufacture of a medicament for treating a neuropathic pain and/or neuropathic pain syndrome or a medicament for combating an inflammation: wherein R1 is selected from hydrogen, halogen, alkyl, cyano and haloalkyl, R2 and R3 are independently selected from hydrogen, halogen, alkyl, haloalkyl and nitro, and R1, R2 and R3 are not hydrogen at the same time; furthermore, when either R2 or R3 is nitro or halogen, the other two of R1, R2 and R3 are not hydrogen at the same time. The compound has good effects in treating a neuropathic pain and/or neuropathic pain syndrome and good effects in combating an inflammation, and has not side effects such as addiction.

Ni-Catalyzed Reductive Cyanation of Aryl Halides and Phenol Derivatives via Transnitrilation

Herein, we report a Ni-catalyzed reductive coupling for the synthesis of benzonitriles from aryl (pseudo)halides and an electrophilic cyanating reagent, 2-methyl-2-phenyl malononitrile (MPMN). MPMN is a bench-stable, carbon-bound electrophilic CN reagent that does not release cyanide under the reaction conditions. A variety of medicinally relevant benzonitriles can be made in good yields. Addition of NaBr to the reaction mixture allows for the use of more challenging aryl electrophiles such as aryl chlorides, tosylates, and triflates. Mechanistic investigations suggest that NaBr plays a role in facilitating oxidative addition with these substrates.

Design, synthesis and antimycobacterial activity of novel imidazo[1,2-a]pyridine-3-carboxamide derivatives

We report herein the design and synthesis of “novel imidazo [1,2-a]pyridine-3-carboxamides (IPAs)” bearing a variety of different linkers, based on the structure of IMB-1402 discovered in our lab. Results reveal that 2,6-dimethyl-N-[2-(phenylamino)ethyl] IPAs with an electron-donating group on the benzene ring as a potent scaffold. Compounds 26g and 26h have considerable activity (MIC: 0.041–2.64 μM) against drug-sensitive/resistant MTB strains, and they have acceptable safety indices against MTB H37Rv with the SI values of 4395 and 1405, respectively. Moreover, N-[2-(piperazin-1-yl)ethyl] moiety was also identified as a potentially alternative linker (compound 31), opening a new direction for further SAR studies.

Synthesis and biological evaluation of novel 3-substituted amino-4-hydroxylcoumarin derivatives as chitin synthase inhibitors and antifungal agents

A series of novel 3-substituted amino-4-hydroxycoumarin derivatives have been designed and synthesized as chitin synthase (CHS) inhibitors. All the synthesized compounds have been screened for their CHS inhibition activity and antimicrobial activity in vitro. The enzymatic assay indicated that most of the compounds have good inhibitory activity against CHS, in which compound 6o with IC50 of 0.10 mmol/L had stronger activity than that of polyoxins B, which acts as control drug with IC50 of 0.18 mmol/L. As far as the antifungal activity is concerned, most of the compounds possessed moderate to excellent activity against some representative pathogenic fungi. Especially, compound 6b was found to be the most potent agent against Cryptococcus neoformans with minimal inhibitory concentration (MIC) of 4 g/mL. Moreover, the results of antibacterial screening showed that these compounds have negligible actions to some tested bacteria. Therefore, these compounds would be promising to develop selective antifungal agents.

Selective bromination of pyrrole derivatives, carbazole and aromatic amines with DMSO/HBr under mild conditions

Bromination of pyrrole derivatives, carbazole and aromatic amines using the DMSO/HBr system affords high yields of the corresponding bromo compounds. Temperature control used in the bromination of anilines helped to promote selective formation of mono- or di-brominated products. Simple operation, low toxicity and high selectivity make this a promising new procedure for the bromination of aromatic compounds.

Palladium-mediated conversion of para-aminoarylboronic esters into para-aminoaryl-11C-methanes

Cross-couplings are an alternative to conventional 11C- methylations which are generally employed in PET tracer synthesis. Therefore, we set out to develop a general procedure for the synthesis of para- 11CH3 labeled aromatic amines from the corresponding para-aminoarylboronic esters in the presence of free amines. Aryl boronic esters containing primary, secondary, and tertiary amines were successfully converted into corresponding labeled methyl derivatives in sufficient radiochemical yield to apply this method for tracer development. This procedure was applied to the labeling of CIMBI-712, a promising candidate for the in vivo imaging of the 5-HT7 receptor in the CNS.

Practical method for parallel synthesis of diversely substituted 1-phenylpiperazines

A simple and practical method to prepare 'libraries' of substituted 1-phenylpiperazine building blocks in parallel format has been developed.